Duchenne News Tags: Edgewise Therapeutics

Edgewise shares positive two-year topline results from the ARCH trial.

Edgewise shares a press release announcing FDA granting Fast Track designation for EDG-5506 for the treatment of Duchenne.

Edgewise announces launch of educational website dedicated to the Becker muscular dystrophy community.

Edgewise releases Winter 2023 newsletter.

Edgewise announces FDA granted EDG-5506 Orphan Drug Designation for Duchenne and Becker and Rare Pediatric Disease Designation for Duchenne.

Edgewise Therapeutics announces an expansion of their clinical development program of EDG-5506.

Edgewise Therapeutics announces positive 12-month topline results from the ongoing ARCH study for Becker muscular dystrophy

On March 30, 2023, Edgewise Therapeutics announced the publication of the article, “Modulating fastskeletal muscle contraction protects skeletal muscle in the animal models of Duchenne muscular dystrophy,” in the Journal...

Edgewsie announces positive 6-moth interim results from the ARCH study

On Sept. 12, 2022, Edgewise Therapeutics released positive 4-month interim data from their open label study in individuals with Becker muscular dystrophy.

On Sept. 7, 2022, Edgewise announced that the FDA has authorized its Phase 2 clinical trial for the treatment of Duchenne. They expect to begin dosing participants in the fourth...

On July 12, 2022, Edgewise Therapeutics shared a press release announcing the opening of the CANYON Phase 2 clinical trial of their investigational compound, EDG-5506, in individuals with Becker muscular...

On June 20, 2022, Edgewise Therapeutics announced positive results from the ARCH open label study of EDG-5506.